Skip to main content

Research Repository

Advanced Search

Making the case for pharmacogenomics in the management of mental health conditions

Berrou, Ilhem; Ramsunder, Adrusha; Palmer, Rachel

Making the case for pharmacogenomics in the management of mental health conditions Thumbnail


Authors

Profile image of Ilhem Berrou

Ilhem Berrou Ilhem.Berrou@uwe.ac.uk
Senior Lecturer in Applied Pharmacology

Adrusha Ramsunder

Rachel Palmer



Abstract

Mental health conditions are the largest single cause of disability in the UK and among the top ten causes of disability worldwide. The prevalence of mental health conditions is increasing rapidly, especially since the COVID-19 pandemic. Overall, they cost the UK economy £118bn each year and are associated with a profound impact on people, their families and communities. Antidepressants and antipsychotics are the most common treatments for mental illnesses; however, these medications are associated with troublesome and often significant adverse drug reactions. It may be possible to identify those patients most at risk of developing severe side effects and those who are unlikely to respond to treatment using their genetics. Pharmacogenomics investigates the effects of inherited gene differences on the pharmacodynamics and pharmacokinetics of drugs and, subsequently, drug exposure and therapeutic effects. This article reviews the management of mental illnesses, and the role of genetics in disease risk and response to treatment. It will also discuss pharmacogenomic testing, guidelines and some of the barriers to its implementation in clinical settings.

Journal Article Type Review
Acceptance Date Jan 5, 2023
Online Publication Date Jan 20, 2023
Publication Date Jan 20, 2023
Deposit Date Jan 22, 2023
Publicly Available Date Feb 21, 2023
Journal The Pharmaceutical Journal
Print ISSN 0031-6873
Publisher Royal Pharmaceutical Society of Great Britain
Peer Reviewed Peer Reviewed
Volume 310
Pages 7969
DOI https://doi.org/10.1211/PJ.2023.1.171747
Keywords Mental illness; antipsychotics; pharmacogenomics; pharmacogenomic testing; PGx
Public URL https://uwe-repository.worktribe.com/output/10373457
Publisher URL https://pharmaceutical-journal.com/article/research/making-the-case-for-pharmacogenomics-in-the-management-of-mental-health-conditions

Files

Making the case for pharmacogenomics in the management of mental health conditions (554 Kb)
PDF

Licence
http://www.rioxx.net/licenses/all-rights-reserved

Publisher Licence URL
http://www.rioxx.net/licenses/all-rights-reserved

Copyright Statement
This is the author’s accepted manuscript of the article Berrou, I., Ramsunder, A., & Palmer, R. (2023). Making the case for pharmacogenomics in the management of mental health conditions. Pharmaceutical Journal, 310, 7969.

DOI: https://doi.org/10.1211/PJ.2023.1.171747.

The final published version is available here: https://pharmaceutical-journal.com/article/research/making-the-case-for-pharmacogenomics-in-the-management-of-mental-health-conditions


Making the case for pharmacogenomics in the management of mental health conditions (273 Kb)
Document

Licence
http://www.rioxx.net/licenses/all-rights-reserved

Publisher Licence URL
http://www.rioxx.net/licenses/all-rights-reserved

Copyright Statement
This is the author’s accepted manuscript of the article Berrou, I., Ramsunder, A., & Palmer, R. (2023). Making the case for pharmacogenomics in the management of mental health conditions. Pharmaceutical Journal, 310, 7969.

DOI: https://doi.org/10.1211/PJ.2023.1.171747.

The final published version is available here: https://pharmaceutical-journal.com/article/research/making-the-case-for-pharmacogenomics-in-the-management-of-mental-health-conditions





You might also like



Downloadable Citations